BioCardia (BCDA) Expected to Announce Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is projected to release its earnings data before the market opens on Wednesday, March 26th. Analysts expect BioCardia to post earnings of ($0.87) per share and revenue of $0.02 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

BioCardia Stock Performance

Shares of BCDA stock opened at $2.66 on Monday. The company has a market capitalization of $12.19 million, a price-to-earnings ratio of -0.64 and a beta of 1.28. BioCardia has a 52-week low of $1.63 and a 52-week high of $6.41. The company has a 50-day simple moving average of $2.42 and a two-hundred day simple moving average of $2.41.

Insider Activity

In other BioCardia news, Director Simon H. Stertzer purchased 22,753 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were bought at an average cost of $2.30 per share, for a total transaction of $52,331.90. Following the purchase, the director now owns 40,602 shares of the company’s stock, valued at $93,384.60. This represents a 127.47 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased 25,353 shares of company stock valued at $58,525 in the last three months. Company insiders own 20.00% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th. Alliance Global Partners raised BioCardia from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 30th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.